Compare Gold Fields Limited (GFI) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gold Fields Limited vs Sanofi SA — how do they compare? Gold Fields Limited trades at $40.98 (market cap $36.07B), while Sanofi SA trades at $43.63 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 2.9× Gold Fields Limited's market cap, and Gold Fields Limited pays the higher dividend (5.76%). Which is the better fit depends on your goals.
| GFI | SNY | |
|---|---|---|
Market Cap | $36.07B | $104.30B |
Sector | Basic Materials | Health |
52-Week High | $61.52 | $52.34 |
52-Week Low | $29.31 | $41.33 |
Enterprise Value | $37.51B | $124.19B |
Dividend Yield | 5.76% | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gold Fields (GFI) trades at $41.06, down 0.16% on the day, with a bullish technical signal from moving averages but bearish oscillators. The company shows strong fundamentals with a P/E of 10.22, net income margin of 40.76%, and robust cash flow growth, with 2025 projections indicating revenue of $8.8B and net income of $3.6B. Recent news highlights institutional buying interest, such as Assenagon Asset Management's new position in Q2 2026.
The outlook for GFI is positive, supported by high profitability and growth projections, though risks include volatile gold prices and cost pressures. Analyst consensus is a Buy with a $52 price target, suggesting 27% upside. Investors should weigh strong cash generation against debt increases and market sentiment shifts.
SNY trades at $43.54, up 0.14% today, with a neutral technical signal and bullish moving averages. Recent Q2 2026 earnings beat expectations, with EPS of $1.21 versus $1.10 expected, driven by strong Dupixent sales. The company raised its 2026 outlook, projecting ~10% sales growth. Financial health is solid with a P/E of 23.27 and robust operating cash flow of $10.75B in 2025, though net cash flow was minimal at $49M.
Outlook is cautiously optimistic with growth catalysts from Dupixent and new drug approvals, but risks include pipeline setbacks and competitive pressures. Analysts are mixed, with 44% buy ratings, highlighting potential upside to fair value estimates around $57, while debt levels and regulatory scrutiny pose challenges for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
